| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| APOE | INS | ENSP00000252486 | ENSP00000380432 | Apolipoprotein E; Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues; Apolipoproteins | Insulin; Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver | 0.848 |
| APOE | MALRD1 | ENSP00000252486 | ENSP00000412763 | Apolipoprotein E; Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues; Apolipoproteins | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | 0.469 |
| APOE | NR1H4 | ENSP00000252486 | ENSP00000447149 | Apolipoprotein E; Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues; Apolipoproteins | Bile acid receptor; Isoform 4- Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, ACA and DCA), NR0B2/SHP (inducible by unconjugated CDCA, ACA and DCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; most efficient isoform compared to isoforms 1 to 3; not inducible by taurine- and glycine-amidated CDCA; Belongs to the nuclear hormone receptor family. NR1 subfamily | 0.483 |
| APOE | SCARB2 | ENSP00000252486 | ENSP00000264896 | Apolipoprotein E; Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues; Apolipoproteins | Lysosome membrane protein 2; Acts as a lysosomal receptor for glucosylceramidase (GBA) targeting; Belongs to the CD36 family | 0.405 |
| CLMP | MALRD1 | ENSP00000405577 | ENSP00000412763 | CXADR-like membrane protein; May be involved in the cell-cell adhesion. May play a role in adipocyte differentiation and development of obesity. Is required for normal small intestine development; I-set domain containing | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | 0.495 |
| CSPG5 | MALRD1 | ENSP00000373244 | ENSP00000412763 | Chondroitin sulfate proteoglycan 5; May function as a growth and differentiation factor involved in neuritogenesis. May induce ERBB3 activation | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | 0.422 |
| FGF19 | INS | ENSP00000294312 | ENSP00000380432 | Fibroblast growth factor 19; Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4; Belongs to the heparin-binding growth factors family | Insulin; Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver | 0.754 |
| FGF19 | MALRD1 | ENSP00000294312 | ENSP00000412763 | Fibroblast growth factor 19; Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4; Belongs to the heparin-binding growth factors family | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | 0.534 |
| FGF19 | NR1H4 | ENSP00000294312 | ENSP00000447149 | Fibroblast growth factor 19; Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4; Belongs to the heparin-binding growth factors family | Bile acid receptor; Isoform 4- Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, ACA and DCA), NR0B2/SHP (inducible by unconjugated CDCA, ACA and DCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; most efficient isoform compared to isoforms 1 to 3; not inducible by taurine- and glycine-amidated CDCA; Belongs to the nuclear hormone receptor family. NR1 subfamily | 0.901 |
| INS | APOE | ENSP00000380432 | ENSP00000252486 | Insulin; Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver | Apolipoprotein E; Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues; Apolipoproteins | 0.848 |
| INS | FGF19 | ENSP00000380432 | ENSP00000294312 | Insulin; Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver | Fibroblast growth factor 19; Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4; Belongs to the heparin-binding growth factors family | 0.754 |
| INS | MALRD1 | ENSP00000380432 | ENSP00000412763 | Insulin; Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | 0.505 |
| INS | NR1H4 | ENSP00000380432 | ENSP00000447149 | Insulin; Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver | Bile acid receptor; Isoform 4- Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, ACA and DCA), NR0B2/SHP (inducible by unconjugated CDCA, ACA and DCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; most efficient isoform compared to isoforms 1 to 3; not inducible by taurine- and glycine-amidated CDCA; Belongs to the nuclear hormone receptor family. NR1 subfamily | 0.835 |
| MALRD1 | APOE | ENSP00000412763 | ENSP00000252486 | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | Apolipoprotein E; Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues; Apolipoproteins | 0.469 |
| MALRD1 | CLMP | ENSP00000412763 | ENSP00000405577 | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | CXADR-like membrane protein; May be involved in the cell-cell adhesion. May play a role in adipocyte differentiation and development of obesity. Is required for normal small intestine development; I-set domain containing | 0.495 |
| MALRD1 | CSPG5 | ENSP00000412763 | ENSP00000373244 | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | Chondroitin sulfate proteoglycan 5; May function as a growth and differentiation factor involved in neuritogenesis. May induce ERBB3 activation | 0.422 |
| MALRD1 | FGF19 | ENSP00000412763 | ENSP00000294312 | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | Fibroblast growth factor 19; Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4; Belongs to the heparin-binding growth factors family | 0.534 |
| MALRD1 | INS | ENSP00000412763 | ENSP00000380432 | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | Insulin; Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver | 0.505 |
| MALRD1 | NAALAD2 | ENSP00000412763 | ENSP00000432481 | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | N-acetylated-alpha-linked acidic dipeptidase 2; Has N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Also exhibits a dipeptidyl-peptidase IV type activity. Inactivate the peptide neurotransmitter N- acetylaspartylglutamate | 0.453 |
| MALRD1 | NR1H4 | ENSP00000412763 | ENSP00000447149 | MAM and LDL-receptor class A domain-containing protein 1; Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis | Bile acid receptor; Isoform 4- Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, ACA and DCA), NR0B2/SHP (inducible by unconjugated CDCA, ACA and DCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; most efficient isoform compared to isoforms 1 to 3; not inducible by taurine- and glycine-amidated CDCA; Belongs to the nuclear hormone receptor family. NR1 subfamily | 0.455 |
